Apellis Has New Hope for Pegcetacoplan With Longer-Term Data
18-Month Results Could Vindicate Geographic Atrophy Program
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
